Cargando…
Coagulopathy in COVID-19 and anticoagulation clinical trials
Severe acute respiratory disease coronavirus 2 (SARS-COV-2) first emerged in Wuhan, China, in December 2019 and has caused a global pandemic of a scale unprecedented in the modern era. People infected with SARS-CoV-2 can be asymptomatic, moderate symptomatic or develop severe COVID-19. Other than th...
Autores principales: | Zhang, Heng, Lao, Qifang, Zhang, Jue, Zhu, Jieqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395291/ https://www.ncbi.nlm.nih.gov/pubmed/36494146 http://dx.doi.org/10.1016/j.beha.2022.101377 |
Ejemplares similares
-
COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation
por: Salabei, Joshua K, et al.
Publicado: (2021) -
Covid-19-induced coagulopathy and observed benefits with anticoagulation
por: Karimzadeh, Sedighe, et al.
Publicado: (2020) -
COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation
por: Miesbach, Wolfgang, et al.
Publicado: (2020) -
Monitoring of COVID-19-Associated Coagulopathy and Anticoagulation with Thromboelastometry
por: Katz, Daniel, et al.
Publicado: (2021) -
Coagulopathy and Plausible Benefits of Anticoagulation Among COVID-19 Patients
por: Ahmed, Syed Imran, et al.
Publicado: (2020)